Nasdaq Biotechnology Ishares (IBB) 343.43 $IBB Array

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nasdaq Biotechnology Ishares (IBB) 343.43 $IBB

Array BioPharma CEO Sees Big Opportunities in the Future
at The Street - 2 hrs 38 mins ago
Ron Squarer, CEO of Array BioPharma, says the company has several late-stage clinical trials underway, and their success could build momentum.
XBI: 225.50 (+1.13), AZN: 68.43 (-1.51), IBB: 343.43 (-7.89), NVS: 98.61 (-2.70), ARRY: 7.37 (-0.17)

Biotech ETFs in Focus after a Choppy Week - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Tue Mar 31, 11:57AM CDT
Biotech ETFs are recovering from one of the worst sell-offs of this year.
PBE: 55.14 (-1.11), SBIO: 29.87 (-0.25), SPY: 206.43 (-1.82), FBT: 118.23 (-2.67), XBI: 225.50 (+1.13), BBH: 129.58 (-3.38), IBB: 343.43 (-7.89)

Big Pharma Merger Monday Deals Disregard Biotech Bubble Talks
at The Street - Tue Mar 31, 8:39AM CDT
Large pharmas continued the shopping spree, paying no attention to whispers of a biotech bubble.
CTRX: 59.54 (-0.29), ADXS: 14.44 (+1.00), UNH: 118.29 (-2.71), HZNP: 25.97 (+0.19), IBB: 343.43 (-7.89), TEVA: 62.30 (-0.22), ASPX: 100.27 (-0.09), NVS: 98.61 (-2.70), HPTX: 45.90 (-0.08)

LifeSci Capital Initiates Coverage of Biotech Exchange Traded Funds (ETFs)
ACCESSWIRE - Tue Mar 31, 7:02AM CDT
Intends to Provide Ongoing Coverage of the Biotech ETF Sector; Report Available here: http://www.lifescicapital.com/equity-research/etf-coverage/
BBP: 31.04 (-0.49), BBC: 32.83 (-0.63), IBB: 343.43 (-7.89)

Strong Dollar Hurts Profit Forecasts In Long Term
Orit Nathan Mahalal - at Seeking Alpha - Tue Mar 31, 7:00AM CDT

BIIB: 422.24 (-9.38), ABX: 10.96 (-0.18), FB: 82.21 (-0.98), IBB: 343.43 (-7.89), GOOG: 548.00 (-4.03), UUP: 25.90 (+0.04), SPY: 206.43 (-1.82), QQQ: 105.60 (-1.13), KGC: 2.24 (-0.05), GLD: 113.66 (-0.09), ALXN: 173.30 (-6.96), DIA: 177.58 (-1.81), XLK: 41.44 (-0.43), GOOGL: 554.70 (-6.44), FXE: 105.71 (-0.61), IWM: 124.37 (-0.40), MSFT: 40.65 (-0.31), AAPL: 124.43 (-1.94), REGN: 451.48 (-8.30), GG: 18.12 (-0.07)

'Fast Money' Recap: A Stock Rally With 'Window Dressing'
at The Street - Tue Mar 31, 4:00AM CDT
The trading panel discussed volatility, GoPro and biotech stocks.
TSLA: 188.77 (-1.80), GPRO: 43.41 (-0.17), SPY: 206.43 (-1.82), GILD: 98.13 (-2.56), C: 51.52 (-0.12), IBB: 343.43 (-7.89), AMGN: 159.85 (-4.45), IWM: 124.37 (-0.40), IYT: 156.62 (-0.84), INTC: 31.27 (-0.19), CELG: 115.28 (-4.74)

Biotech Weekly: Top Value Biotech Picks Starting Q2 2015
Daniel Ward - at Seeking Alpha - Mon Mar 30, 8:43AM CDT

LOXO: 12.45 (-0.10), TENX: 3.26 (+0.12), QLTI: 3.91 (-0.02), ECYT: 6.26 (-0.03), TNXP: 6.32 (+0.05), BOTA: 2.30 (+0.04), XBI: 225.50 (+1.13), DARA: 0.73 (-0.03), IBB: 343.43 (-7.89), MEIP: 1.79 (+0.04)

Is Gilead Sciences Inc. About to Crater Before Our Very Eyes?
George Budwell, The Motley Fool - Motley Fool - Sun Mar 29, 9:02AM CDT
Gilead Sciences ' stock has been something of an enigma for biotech investors of late. Despite a 122% increase in revenue last year due primarily to the launch of its hepatitis C drugs Sovaldi and Harvoni, strong growth prospects going forward, and...
GILD: 98.13 (-2.56), ACHN: 9.86 (-0.38), MRK: 57.48 (-0.86), IBB: 343.43 (-7.89), ABBV: 58.54 (+0.30)

The 'End Game' - My Take On Indicators Leading To The End Of The U.S. Bull Market
Robert Duval - at Seeking Alpha - Sun Mar 29, 2:53AM CDT

SPY: 206.43 (-1.82), QQQ: 105.60 (-1.13), DIA: 177.58 (-1.81), IBB: 343.43 (-7.89), IWM: 124.37 (-0.40)

Weighing The Week Ahead: Time For An Economic Spring Thaw?
Jeff Miller - Seeking Alpha - Sun Mar 29, 12:57AM CDT
In the absence of real data it is easy and tempting to speculate. Unlike last week, the week ahead features an avalanche of data - more in both quantity and importance than we have seen in a month. With some recent significant reports showing...
IBB: 343.43 (-7.89), SPUU: 141.61 (-2.57), SPLX: 31.76 (+0.67), TQQQ: 102.99 (-3.29), SDOW: 19.71 (+0.59), DOG: 23.05 (+0.23), SPXU: 35.99 (+0.92), UPRO: 133.46 (-3.56), SPY: 206.43 (-1.82), EPS: 71.58 (-0.52), DXD: 21.26 (+0.43), QQXT: 41.44 (-0.37), SQQQ: 26.76 (+0.84), DIA: 177.58 (-1.81), SPXL: 88.44 (-2.36), QID: 36.86 (+0.78), SFLA: 159.00 (unch), RWL: 41.45 (-0.26), RSP: 81.05 (-0.56), SH: 21.46 (+0.19), SSO: 129.30 (-2.34), QQEW: 43.80 (-0.43), IVV: 207.83 (-1.79), QQQE: 65.30 (-0.53), DDM: 134.00 (-2.96), QLD: 142.55 (-3.35), VOO: 189.20 (-1.68), QQQ: 105.60 (-1.13), SDS: 21.33 (+0.37), PSQ: 57.55 (+0.59), UDOW: 139.66 (-4.56)

Stocks Finish Lower for the Week as Fed Talk Spooks Investors
at The Street - Fri Mar 27, 3:20PM CDT
Wall Street ends its four-day losing streak on Friday, but the minor gains are nowhere near enough to erase big losses suffered over the week.
BIIB: 422.24 (-9.38), VRTX: 117.97 (-3.28), BMRN: 124.62 (-4.51), MON: 112.54 (-0.84), IBB: 343.43 (-7.89), SOXX: 94.02 (-1.07), NXPI: 100.36 (-2.07), KMX: 69.01 (-0.21), AYI: 168.16 (-4.41), AA: 12.92 (-0.04), TXN: 57.18 (-0.82), ADI: 63.00 (-1.81), ALXN: 173.30 (-6.96), AVGO: 126.98 (-3.57), REGN: 451.48 (-8.30)

Stock Markets Hold Onto Slight Gains Ahead of Yellen Speech
at The Street - Fri Mar 27, 2:11PM CDT
Stocks inch higher on Friday afternoon, recovering from an earlier drop.
BIIB: 422.24 (-9.38), VRTX: 117.97 (-3.28), BMRN: 124.62 (-4.51), GME: 37.96 (+0.27), OLN: 32.04 (-0.37), BBRY: 8.93 (+0.13), IBB: 343.43 (-7.89), HPQ: 31.16 (-0.41), YHOO: 44.44 (-0.51), ALXN: 173.30 (-6.96), DOW: 47.98 (-0.70), REGN: 451.48 (-8.30)

Young Investors Should Hope for a Pullback Sooner Rather Than Later
at The Street - Fri Mar 27, 1:53PM CDT
The CNBC 'Fast Money Halftime' traders discuss attributes young investors should look to develop for the markets, while a market pro weighs in with his top picks.
AMZN: 372.10 (-2.49), ZIOP: 10.77 (-0.84), XBI: 225.50 (+1.13), IBB: 343.43 (-7.89), INXN: 28.20 (+0.14), TLT: 130.69 (+0.28), TBT: 41.87 (-0.20), LEN: 51.81 (+0.32), SPY: 206.43 (-1.82), QQQ: 105.60 (-1.13), XHB: 36.86 (+0.01), P: 16.21 (-0.18), GILD: 98.13 (-2.56), KITE: 57.68 (-2.30), PHM: 22.23 (-0.21), DIA: 177.58 (-1.81), ITB: 28.23 (-0.03), JUNO: 60.66 (-0.09), IWM: 124.37 (-0.40), KBH: 15.62 (-0.04), AAPL: 124.43 (-1.94), ZU: 12.99 (-0.38), BABA: 83.24 (-0.66)

A Buyback Or Biotech Bubble?
Leo Kolivakis - Seeking Alpha - Fri Mar 27, 1:37PM CDT
(click to enlarge) Steven Davidoff Solomon, professor of law at the University of California, Berkeley, wrote a comment for the New York Times reports, General Motors' Stock Buyback Follows a Worrying Trend : General Motors' announcement that...
BIIB: 422.24 (-9.38), GILD: 98.13 (-2.56), XBI: 225.50 (+1.13), IBB: 343.43 (-7.89), PKW: 49.31 (-0.38), CELG: 115.28 (-4.74)

Biotech’s Busted — Here’s What To Do Now…
Greg Guenthner - Daily Reckoning - Fri Mar 27, 10:41AM CDT
This post Biotech’s Busted — Here’s What To Do Now… appeared first on Daily Reckoning . Biotechs blasted lower all week. Semiconductors hit the mat. And the once high-flying Nasdaq lost more than 3% as of yesterday—topping off its worst...
IBB: 343.43 (-7.89), IWM: 124.37 (-0.40), XLV: 72.50 (-1.28)

Jim Cramer -- There's No Bubble in Biotech or Semiconductor Sectors
at The Street - Fri Mar 27, 10:23AM CDT
Some of Cramer's favorite companies are rising with their sectors Friday.
BIIB: 422.24 (-9.38), QRVO: 79.70 (-1.70), SWKS: 98.29 (-1.84), IBB: 343.43 (-7.89), SMH: 55.30 (-0.56), NXPI: 100.36 (-2.07), REGN: 451.48 (-8.30), AVGO: 126.98 (-3.57), CELG: 115.28 (-4.74)

Pharmacyclics, BioMarin, And Incyte: A Quick Screen
William Meyers - at Seeking Alpha - Thu Mar 26, 4:30PM CDT

PCYC: 255.95 (-0.48), BMRN: 124.62 (-4.51), INCY: 91.66 (-2.53), IBB: 343.43 (-7.89)

'Fast Money' Recap: ‘Nervousness’ Surrounds Quarterly Earnings Results
at The Street - Thu Mar 26, 1:57PM CDT
The CNBC ‘Fast Money Halftime’ traders analyze earnings and the impact of the strong dollar, as well as the unrest in the Middle East and SanDisk’s lowered guidance.
MU: 27.13 (+0.45), QCOM: 69.34 (+0.46), IBB: 343.43 (-7.89), INTC: 31.27 (-0.19), SNDK: 63.62 (-1.36)

Stocks Turn Flat in Bumpy Session; Crude Settles Above $51
at The Street - Thu Mar 26, 1:53PM CDT
Stocks recover from heavy losses suffered earlier Thursday.
IBB: 343.43 (-7.89), MYL: 59.35 (-0.65), LULU: 64.02 (-0.81), SLB: 83.44 (-1.04), CELG: 115.28 (-4.74), GILD: 98.13 (-2.56), ALXN: 173.30 (-6.96), RHT: 75.75 (-0.94), TWC: 149.88 (+0.61), CMCSA: 56.47 (-0.14)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 43

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 37

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 47

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 34

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 44

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 38

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading

Top 5 Most Recently Viewed Articles

Analyzing the P/E Ratio of Western Alliance: Insights and Trends

Updated Category News Views 123

Understanding the P/E Ratio of Western Alliance In the current market climate, Western Alliance Inc. (WAL) has seen its share price hit $79.17, reflecting a modest increase of 0.47%. Over the past month, however, the stock has experienced a decrease of 6.61%. Interestingly, despite this recent dip, when we look at the yearly perspective, the stock has climbed by 6.77%...

Continue Reading
Hesai Group Innovates Lidar Technology for Cadillac SUVs

Updated Category News Views 219

Hesai Group Powers Cadillac's VISTIQ with Advanced Lidar Technology Hesai Group, a prominent player in lidar technology, has achieved a significant milestone by partnering with SAIC-GM to integrate its advanced AT series lidar system into Cadillac's new all-electric VISTIQ SUV. This integration represents a breakthrough in automotive design and technology, as it is the...

Continue Reading
Jeffersonville Bancorp Reports Strong Q2 Earnings and Dividend

Updated Category News Views 121

Jeffersonville Bancorp Delivers Impressive Earnings for Q2 Jeffersonville Bancorp, Inc. (OTCQB - JFBC) reported robust second quarter results, showcasing a net income of $3,290,000, equivalent to $0.78 per share. This financial performance indicates a notable increase from the previous year's earnings of $3,031,000, or $0.72 per share, reflecting a significant rise in...

Continue Reading
SAS, NPower Team Up: Disrupting Tech Career Access

Updated Category News Views 12

An Unlikely Alliance Fueling Tech Careers Not every day do you see a big-name data firm strut their stuff in the nonprofit world. SAS has teamed up with NPower to flip the script on tech career access. This isn't just a side project—it's a full-throttle mission to drive hardcore data understanding into communities that have long been left hanging. Right here in Cary,...

Continue Reading
America's Emotional Landscape: Loneliness and Division Exposed

Updated Category News Views 216

Understanding the Impact of Societal Division on Emotional Health Most U.S. adults report feeling isolated, in need of more emotional support Loneliness and a sense of emotional disconnection are increasingly shaping the lifes of individuals in America. Recent findings reveal that a significant majority of U.S. adults feel stressed due to societal division. This insight...

Continue Reading